Share ownership Genmab A/S

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen Other stock markets 16:20:00 08/12/2025 GMT			5-day change	1st Jan Change
2,056.00 ^DKK	+1.18%		+0.64%	+37.76%

06:30am	Genmab Presents Promising Data for Epcoritamab in Richter's Transformation	FW
12-08	Genmab Epcoritamab Achieves Up to 73% Complete Response Across Richter Transformation Trial Arms	MT

Share class: Genmab A/S

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	66,187,186	63,498,948 ( 95.94 %)	2,647,007 ( 3.999 %)	95.94 %

Major shareholders: Genmab A/S

Name	Equities	%	Valuation
GENMAB A/S 4.128 %	2,651,727	4.128 %	840 M kr
Orbis Investment Management Ltd. 4.08 %	2,620,635	4.08 %	830 M kr
Jan van de Winkel 0.9816 %	630,588	0.9816 %	200 M kr
Nykredit Bank A/S (Investment Management) 0.5223 %	335,523	0.5223 %	106 M kr
AllianceBernstein Investments Taiwan Ltd. 0.4659 %	299,280	0.4659 %	95 M kr
Robert W. Baird & Co., Inc. (Equity) 0.3184 %	204,509	0.3184 %	65 M kr
Sjunde AP-fonden 0.1501 %	96,412	0.1501 %	31 M kr
Candriam SCA 0.1251 %	80,360	0.1251 %	25 M kr
State Street Global Advisors Ltd. 0.1136 %	72,968	0.1136 %	23 M kr
Arca Fondi SGR SpA 0.1104 %	70,916	0.1104 %	22 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Name	Equities	%	Valuation
Orbis Investment Management Ltd. 1.725 %	11,078,006	1.725 %	358 M kr
AllianceBernstein LP 1.705 %	10,953,913	1.705 %	354 M kr
Paradigm BioCapital Advisors LP 0.5942 %	3,816,851	0.5942 %	124 M kr
Arrowstreet Capital LP 0.5671 %	3,643,139	0.5671 %	118 M kr
Harding Loevner LP 0.5424 %	3,484,487	0.5424 %	113 M kr
Aperio Group LLC 0.5155 %	3,311,449	0.5155 %	107 M kr
Renaissance Technologies LLC 0.4392 %	2,821,543	0.4392 %	91 M kr
First Trust Advisors LP 0.2627 %	1,687,388	0.2627 %	55 M kr
Eaton Vance Management 0.2607 %	1,674,574	0.2607 %	54 M kr
Two Sigma Advisers LP 0.223 %	1,432,800	0.223 %	46 M kr
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	101.45%
Other	5.08%
Genmab A/S	4.13%
Individuals	1.06%
SEI Investments Co.	0.11%
Fifth Third Bancorp	0.06%
Regions Financial Corp.	0.02%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	78.36%
Bermuda	21.32%
Denmark	4.82%
United Kingdom	2.17%
Individuals	1.06%
Canada	0.75%
Norway	0.53%
Taiwan	0.47%
Ireland	0.34%
France	0.31%
Switzerland	0.28%
Luxembourg	0.27%
Sweden	0.25%
Finland	0.2%
Italy	0.19%
Australia	0.16%
Germany	0.15%
Belgium	0.06%
Cayman Islands	0.05%
Hong Kong	0.04%
Japan	0.02%
Austria	0.02%
Portugal	0.02%
Singapore	0.01%
Netherlands	0.01%
China	0.01%
New Zealand	0.01%
Spain	0.01%
South Africa	0.01%
Mexico	0.01%

Based on 1000 largest holdings

Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (80.6%); - income from research and development (9.3%); - other (10.1%): primarily income from partnership agreement. At the end of 2024, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Net sales are distributed geographically as follows: Denmark (91.9%), the United States (4.2%) and Japan (3.9%).

Employees

2,681

Sector

Biotechnology & Medical Research

Calendar

08/12/2025 - American Society of Hematology Meeting - Abstract No:5511

More about the company